Available online at www.sciencedirect.com
SCIENCE DIRECT®
Pharmacology, Biochemistry and Behavior 75 (2003) 949–952
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
www.elsevier.com/locate/pharmbiochembeh

VOLUME 75, 2003
KEYWORD INDEX

Acetone, 199
Acetylcholinesterase, 645, 661
Acetylcholinesterase inhibitors, 513
Acoustic startle response, 163
Activate, 749
Activity, 17
Activity cage, 381
Acute effects, 669
Acute withdrawal, 411
Addiction, 607
Adjuvant, 181
Adolescence, 163, 411
Adolescent, 355
Adrenal gland, 823
β-Adrenoceptors, 81
Aging, 147, 921
Alcohol, 481, 881
Alcohol intake, 593
Alcohol-nonpreferring (NP) rats, 163
Alcohol-preferring (P) rats, 163
Alcohol-preferring rats, 89, 593
Alcohol-seeking behavior, 89
Alcohol withdrawal, 619
Allopregnanolone, 397
Allopregnanolone (3α,5α-tetrahydro-progesterone), 831
Alprazolam, 75
Alzheimer's dementia, 381
Alzheimer's disease, 513, 651, 675
Aminotransferases, 823
Amphetamine, 191
Analgesia, 909
Anesthetics, 435
Antagonism, 661
Antagonist, 909
Anticholinesterase, 651
Antidepressant, 247, 405, 557
Antiepileptic drugs, 319
Antihypertensive agents, 265
Anti-inflammatories, 513
Anti-inflammatory, 651
Antinociception, 115, 447, 459, 763
Antinociceptive, 261
Antioxidant, 651
Antioxidants, 513
Antipsychotic, 133
Antipsychotic drugs, 255
Antistress adaptogenic activity, 547
Anxiety, 355, 411, 529, 711, 741, 763, 869
Anxiety-like behavior, 619
Anxiogenic, 741
Anxiolysis, 537
Anxiolytic, 903
Anxiolytic effects, 89
Anxiolytic-like effects of androgens, 473
Apis mellifera, 217
Apocynum venetum, 557
Apomorphine, 191, 565
Appetitive conditioning, 89
Approach avoidance, 861
Apyrase, 467
L-arginine, 329
Associative learning, 141
Attention, 687, 711, 721, 915
Attention deficit hyperactivity disorder, 209
Autoreceptor, 769
Aversive conditioning, 89
Ayahuasca, 501

Baboons, 435
Bacopa monniera, 823
Banisteriopsis caapi, 627
Behavior, 123, 795, 861
Behavioral sensitization, 49
Behaviour, 67, 565
Benzine, 199
Benzodiazepine, 75, 619
Benzodiazepine anxiolytic, 247
Benzodiazepine binding site, 537
Benzodiazepines, 435
Beta-funaltrexamine, 301
Binocular depth inversion, 789
Blood glucose, 915
Blood serum, 467
Body temperature, 881
Body weight, 341
BP897, 363
Brain damage, 795
Brain damage recovery, 381
Brain stimulation reward, 199

Caffeine, 921
Calcineurin, 749
Cannabinoid, 565, 763
Cannabinoid agonist, 809
Cannabinoid antagonist, 809
Cannabinoid CB_1 receptor, 777
Cannabinoids, 577, 585
Cannabis, 789
Capillary electrophoresis, 35
Capsaicin, 115
Capsazepine, 115
Captopril, 265
Caudate putamen, 123
Caudate–putamen, 895
C57BL/6J mice, 273
CD26, 869
Cephalopod, 141
Cerebral blood velocity, 309
Chlordiazepoxide, 435
Chloride uptake, 619
8-Chlorotheophylline, 173
Choice reaction time test, 915
Cholinergic, 669
Cholinergic system, 217
Cholinesterase, 675
Choto-san, 635
Chronic stress, 419
Chronic unpredictable footshock stress, 547
Chronopharmacology, 881
Circadian rhythm, 881
Clearance of charcoal particles, 749
Clitoria ternatea, 529
Clozapine, 895
CNS, 537
CNS-depressant, 261
CNS plants, 501
Cocaine, 49, 123, 273, 301, 801, 837

Cognition, 687, 755
Cognitive behavior, 529
Cognitive deficits, 645
Cognitive enhancer, 675
Cognitive function, 921
Cognitive functions, 381
Cognitive impairment, 35, 789
Coloboma, 209
Conditioned drug effects, 273
Conditioned fear stress, 903
Conditioned lick suppression, 281
Conditioned place preference, 173, 289, 295
Conditioning, 9
Conflict behavior, 397, 481
Contextual fear, 491
Convulsions, 329, 529
cotinine, 1
CP 93, 129, 147
Creatine kinase, 823
Cuttlefish, 141
Cyclohexane, 199
Cycloheximide, 141

Daidzin, 593
Dehydration, 341
Delayed-type hypersensitivity, 749
Dementia, 513
Dependence, 349
Depression, 419, 529, 769
Descending serotonergic system, 447
Desensitization, 115
Desipramine, 247
Developmental, 295
Diabetes, 247, 255
Diazepam, 247, 473
Differential effects of benzodiazepines, 473
5,7-Dihydroxytryptamine, 381
Dimenhydrinate, 173
Dipeptidyl-peptidase IV, 869
Diphenhydramine, 173
Diuresis, 235
2-DM-DOM, 845
5-DM-DOM, 845
DOI, 191
[−]-DOM, 405
(−)-DOM, 845
DOM metabolites, 845
DOPAC, 777
Dopamine, 191, 209, 419, 557, 577, 607, 777, 895
Dopamine agonist, 363
Dopamine antagonist, 363
Dopamine D3 receptor, 373
Dopamine D_1 receptor binding, 123
Dopamine receptors, 289, 565
Dopamine release, 627
Dorsal diencephalic conduction system, 607
dPAG, 25
Dramamine, 173
Drinking, 373
Drug discrimination, 427, 435, 837
Drug-induced stimulus control, 405
Drug interaction, 75
Drug interactions, 319
Drug self-administration, 607
Drug sensitization, 103
Drug tolerance, 103
DSP-4, 209

EEG, 701
EFC, 749
Eight-arm maze, 795
Eight-arm radial maze, 335
Electroencephalograph, 701
Electroshock maximal, 319
Elevated plus-maze, 741
Elevated plus maze, 869
Ephedra spp., 501
(−)Epicatechin, 635
Epilepsy, 853
Escitalopram, 903
Essential oil, 651
Ethanol, 89, 223, 411, 837
Ethanol, conditioned place preference, 373
Evaporative water loss, 341
Evoked potentials, 701
Excitatory conditioning theory of sensitisation, 273
Exercise, 81
Exploration, 861
Exploratory activity, 355

F344, 869
Fear, 25, 89
Feeding, 181
Feeding motivation, 869
Female, 181
Fetal alcohol, 17
Finasteride, 889
FK506, 853
Flavonoids, 537
Flavor conditioning, 223
Flavor–flavor learning, 55
Flunitrazepam, 481
Fluoxetine, 247
Fluvoxamine, 247
Food intake, 341, 869
Forced swim, 769
Forehead skin perfusion, 309
Formalin test, 447
Free radicals, 853
Frontal cortex, 645
Frontal function, 711
Frontal lobe function, 721

GABA, 481
GABA-A, 397
GABA(A) and 5-HT_{2C} receptors, 619
$GABA_A$ receptor, 481, 537, 837
Gastric infusions, 223
Geissoschizine methyl ether, 635
Gender, 235
Generalized absence epilepsy, 889
Genetic, 17
Ginkgo, 701
Ginkgo, 711
Ginseng, 687, 701
Glucose, 823
Glucose transport, 255
Gravol, 173
Guaraná, 501

Habenulo-interpeduncular pathway, 607
Haloperidol, 133, 895
Hangover, 881
Harmaline, 627
Harmine, 627
Head-twitch response, 777
Heat exposure, 341
Herbal medicine, 419
Heroin, 75, 349
Hesperidin, 537
5-HIAA, 777
Hippocampus, 645
Histamine, 25
Hole-board test, 741
HPG axis, 481
H_2 receptors, 25
5-HT, 903
5-HT_{1A}, 81
5-$HT_{2A/2C}$, 81
$5HT_3$ antagonists, 1
5-HT_{2A} receptor, 777
5-HT_{2A} receptors, 459
Huperzine A, 675
HVA, 777
Hydralazine, 265
Hyperactivity, 209
Hyperglycemia, 255
Hypnosis, 537
Hypnotic, 261
Hypoglycemia, 915

Iboga, 501
Iboga alkaloids, 607
Ibogaine, 593, 607
Ibogaine analog, 593
IC50 inhibition, 661
IL-1β, 181
Imidazenil, 435
Imidazoline I_2-site, 427
Immobilization stress, 823
Impulsivity, 481
Indole alkaloid, 627
Indole alkaloids, 635
Inferior colliculus, 25
Inhalants, 199
Intact versus castrated males, 473
Interval timing, 9
Intracerebroventricular injections, 491
Intraplantar injection, 115
Intraseptal injections, 491
In vivo, 427
In vivo microdialysis, 607
Isobolographic analysis, 319
Isoflavones, 721
Isradipine, 265, 801

Kava-kava, 501
Ketanserin, 459
Khat, 501
Kindling, 853
Kudzu, 593

Lactation, 733
Latent inhibition, 281
Lateral septum, 397
l-12-Chloroscoulerine, 289
Lead, 295
Learning, 329, 585, 861
Light–dark test, 741
Lipids, 823
Lithium, 341
Lithium chloride, 35
Locomotor activity, 173, 363
Longitudinal, 921
Long-term depression, 585
Long-term memory, 141
Long-term potentiation, 585
LSD, 845

M100907, 845
Male, 181
MAOI, 627
Marapuama, 645
Marijuana, 309
Medicinal plants, 501
Melatonin, 67
Memory, 329, 669, 687, 711, 721, 861
Menopause, 711, 721
Mesocorticolimbic pathways, 607
18-Methoxycoronaridine, 607
6-Methylapigenin, 537
Methylphenidate, 67
Mice, 363, 373, 763
Midazolam, 435, 491
Midbrain tectum, 25
Monkeys, 435
Monoamine oxidase inhibition, 627
Monoterpenoids, 651
Mood, 687, 721
Morphine, 289, 295, 349, 929
Morphine self-administration, 577
Motor activity, 67
Mouse, 115, 447, 741
Mouse mutant, 209
Mouse strain differences, 123
Mu opioid, 363

Nabilone, 585
NAC1, 49
Naltrexone, 447, 459, 801
L-NAME, 265, 329
Natural product, 675
NCAM, 861
Nefazodone, 405
Neonicotinoid, 217
Neophobia, 491
Neurochemical systems interaction, 381
Neuroleptic, 9
Neuropeptide Y, 869
Neuroprotection, 853
Neuroprotective, 675
Neuropsychological testing, 915
Neurotoxicity, 795
Neurotrophins, 81
N^G-Nitro-D-arginine methyl ester, D-NAME, 741
N^G-Nitro-L-arginine methyl ester, L-NAME, 741
Nicotine, 355
Nicotine patch, 1
Nicotine withdrawal, 1
Nicotinic receptor agonist, 217
α3β4 Nicotinic receptors, 607
Nitric oxide, 265, 741
Nitric oxide synthase inhibitor, 741
NO, 329
Nonassociative learning, 217
Noradrenergic, 103
Norepinephrine, 209, 427, 557, 755
Novelty seeking, 929
NPI-031G, 619
5′-Nucleotidase, 467
Nucleotide hydrolysis, 467
Nucleus accumbens, 123

Obesity, 103
Oestrogenic, 651
Olanzapine, 133
Olfactory tubercle, 123
Ontogenesis, 929
Open-field, 809
Open field, 929
Opiate, 75
Opioid, 349, 763
μ-Opioid receptor, 909
Opioid receptor antagonist, 447
Opioid receptors, 459
Opioid-related processes, 577
Opioids, 235, 801
Oxotremorine, 147

Paced auditory serial addition task, 915
Panax, 687
Panax ginseng, 547
Panax quinquefolium, 823
Parkinson's disease, 627
Passiflora, 501
Passive avoidance training, 141
Penile erection dysfunction, 265
Pentobarbital, 435
Perinatal exposure, 565
Perinatal Δ^9-THC exposure, 577
Pharmacotherapy, 593
Phencyclidine (PCP), 335
Phenolic compounds, 635
Physostigmine, 491
Phytoestrogens, 721
Picrotoxin, 733
Pineal gland, 67
Placebo response, 273
Place conditioning, 929
Place preference, 75
Plant adaptogens, 501
Plants, 513
Plasma THC levels, 309
Poecilia latipinna, 35
Polyuria, 341
Postural syncope, 309
Power, 701
PPHT, 289
Prefrontal cortex, 419
Premna tomentosa, 261
Prepulse inhibition, 163, 191, 281
Progesterone, 889
Progressive ratio, 301
Propofol, 435
Protein synthesis inhibition, 141
Psychosis, 755
Ptychopetalum olacoides, 645
PTZ, 853
Puerarin, 593

Quinpirole, 565

Raclopride, 55
Ranitidine, 25
Rat, 67, 281, 405, 411, 419, 427, 467, 481, 585, 733, 755, 837, 845
Rats, 133, 199, 349, 491, 809
R-citalopram, 903
Reactivity, 163
μ Receptor, 301
β-receptor regulation, 557
5α-reductase, 889
Reference memory, 35
Rehydration, 341
Reinforcement, 75
Release, 777
Restraint, 769
Reward, 75, 173
Reward, reinforcement, 373
Rhynchophylline, 635
Ritalin, 67
(R)-Methanandamide, 809
Rotarod performance, 419
Rotational behavior, 895
R,*S*-citalopram, 903
Ruthenium red, 115

Saccharin, 223
Saccharin, SCH23390, 55
Sage, 669
Saiko-ka-ryukotsu-borei-to, 419
Salvia, 661
Salvia, 669
SCH23390, 289
Schizophrenia, 191, 255, 281, 335
Scratching, 777
Sedation, 537, 869
Seizures, 319
Seizure susceptibility, 831
Self-administration, 301, 349, 373
Sensitization, 173
Sensorimotor gating, 163
Sepia officinalis, 141
Serotonergic, 103
Serotonin, 191, 381, 419, 427, 557, 755, 777
Sex, 265
Sex differences, 235
Sexual behavior temporal patterning, 265
Shock-induced behavioral inhibition, 481
SKF105111, 831
S. lavandulaefolia, 651
Sleep, 881
SNAP-25, 209
Social interaction test, 619, 869
Social isolation, 831
Solvents, 199
Spatial memory, 147
Spike-wave discharges, 889
Spinal cord, 909
Spleen, 823
SR-141716, 809
SR 141716A, 777
SR 46349B, 777
SSRI, 247
Startle, 191
Step-down-type passive avoidance, 749
St. John's wort, 593
Strain, 191
Stress, 467, 529, 769
Striatum, 645
Sucrose, 223
Sweet taste, 55
Synergism, 661

Tail shock, 769
Tail suspension test, 247
Teratogen, 17
Terpenes, 661
Testosterone, 481
Testosterone propionate, 473
THC, 309
Thirst, 341
Thymus, 823
Tiagabine, 319
Time perception, 9
Time production, 9
Tolerability, 651
Toluene, 199
Tracking test, 915
Trafficking proteins, 909
Type I 5α-reductase inhibitor, 831

UK 14, 147, 304
Uncaria sinensis, 635
Up-regulation, 909
Urination, 235
Urine output, 341

Valeriana, 501
Valeriana, 537
Vasopressin, 67
Verbal reaction time, 915
Vertical hole-board, 381
VlPAG, 459
Visual perception, 789
Vomit, 777
Vomiting, 777

WAG/Rij rats, 889
Water intake, 341
Water maze, 147, 381, 585
Water-maze, 861
Weight gain, 133
Withania somnifera, 547
Working memory, 35, 335

Zolpidem, 435
Zuclopenthixol, 755